A phase Ib/II TBCRC032 study has investigated the safety and effectiveness of the androgen receptor antagonist enzalutamide in combination with the PI3K inhibitor taselisib in patients with metastatic AR‐positive (≥10%) breast cancer, including TNBC. This evidence concerns the gene PIK3CD and breast cancer.